Delcath receives first commercial order for CHEMOSAT system from IEO

Delcath Systems, Inc. (NASDAQ: DCTH) announced today that it has received  the first commercial order for the Company's Hepatic CHEMOSAT® Delivery System from the European Institute of Oncology (Instituto Europeo di Oncologia – IEO) –a premier cancer treatment and research center in Europe. Delcath previously announced an initial launch and training agreement with the IEO on November 21, 2011.

"The first commercial order of our CHEMOSAT system is a significant milestone in Delcath's history, marking our transition from a research and development organization to a commercial enterprise," said Eamonn P. Hobbs, President and CEO of Delcath. "With the recent announcement of our fifth EU training center, we believe our launch plans for Europe are on track, and we expect to announce additional center agreements in the coming months. Meanwhile, the hiring and training of our direct sales force is gathering pace, the staffing of our contract medical science liaison team is continuing and we are evaluating potential third-party distribution partners to cover each of our targets markets in Southern Europe. We believe that our momentum is building and we are taking critical steps toward our goal of establishing CHEMOSAT as a new treatment option for patients with cancers in the liver in Europe."